A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Olaparib (Primary) ; Onalespib (Primary)
- Indications Adenocarcinoma; Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- 15 Jun 2017 Planned End Date changed from 31 Oct 2019 to 1 Jun 2020.
- 15 Jun 2017 Planned primary completion date changed from 31 Oct 2019 to 1 Jun 2020.
- 15 Jun 2017 Status changed from not yet recruiting to recruiting.